Hereditary Angioedema Clinical Trials

A listing of Hereditary Angioedema medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 5 clinical trials
Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks

This phase 3b study will evaluate long-term safety and efficacy of CSL312 (also known as garadacimab) when administered subcutaneously (SC)

angioedema
  • 0 views
  • 27 Jul, 2021
  • 11 locations
Expanded Access Program With Lanadelumab for Japanese People With Hereditary Angioedema

angioedema attacks. Lanadelumab is not yet licensed for use in Japan. The main aim of this study is to allow Japanese teenagers and adults with type I or type II hereditary angioedema to be treated

angioedema
bilateral oophorectomy
  • 0 views
  • 19 Jul, 2021
  • 10 locations
Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema

This study evaluates the efficacy of orally administered PHA-022121 for the acute treatment of attacks in patients with hereditary angioedema (HAE). Eligible subjects are randomized to one of

angioedema
  • 0 views
  • 24 Jul, 2021
  • 22 locations
Contrast-Enhanced Ultrasound for the Evaluation of Changes in Tumor Blood Flow Surrounding HAE

The purpose of the study is to find out if a study agent called Lumason microbubbles may be helpful for people with lesions in the liver. It is possible it may help determine an early response to radioembolization and/or help demonstrate radiation toxicity to the surrounding liver.

tumor burden
serum bilirubin
carcinoma
hepatocellular carcinoma
measurable disease
  • 0 views
  • 22 Jul, 2021
  • 1 location
Firazyr Patient Registry (Icatibant Outcome Survey - IOS)

The Icatibant Outcome Survey (IOS) is a prospective, observational disease registry designed to document the routine clinical outcomes over time in participants with angioedema treated with Firazyr (icatibant) and/or Cinryze (C1 inhibitor [human]) in countries where it is currently approved. The data collected will be used to evaluate the safety …

cinryze
angioedema
c1 inhibitor (human)
icatibant
  • 294 views
  • 28 Jul, 2021
  • 107 locations